The Invesco Perpetual UK Growth Fund aims to achieve capital growth in the UK. The fund intends to invest primarily in companies listed in the UK. In pursuing this objective the fund managers may include investments that they consider appropriate which include transferable securities, money market instruments, warrants, collective investment schemes, deposits and other permitted investments and transactions as detailed in Appendix 2 of the most recent Prospectus.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 7.0% |
BP | 5.6% |
BG | 5.2% |
BAE Systems | 4.9% |
BG | 4.5% |
Rentokil Initial | 4.4% |
AstraZeneca | 4.3% |
Imperial Tobacco | 4.1% |
Legal & General | 3.9% |
Roche | 3.4% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 7.0% |
BP | 5.6% |
BG | 5.2% |
BAE Systems | 4.9% |
Other | 77.3% |
Date | 21-Nov-2024 |
---|---|
NAV | 1,014.00p |
Currency | GBP |
Change | 0.47p |
% | 0.05% |
YTD change | 92.15p |
YTD % | 10.00% |
Fund Inception | 12/06/1987 |
---|---|
Fund Manager | Ed Burke |
TER | 1.69 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | £100 |
Savings | £20 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.66% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.10 |
You are here: research